直接抗病毒药物治疗对丙型肝炎相关失代偿期肝硬化新发病例的人群影响:一项全国性记录链接研究
该研究基于苏格兰全国监测数据链接分析,评估无干扰素直接抗病毒药物(DAA)对HCV相关失代偿期肝硬化(DC)的影响。结果显示DAA时代获得持续病毒学应答的患者规模扩大,HCV相关DC新发病例趋势显著改变,2018年降至69例,较前下降51%,估计2015-18年避免330例DC。
要点
- 全国性DAA治疗规模扩大与HCV相关DC新发病例快速下降相关
- DAA时代DC新发病例趋势变化率比为0.88(95%CI 0.85-0.90)
- 2015-18年估计避免330例DC病例
核心结论
- 全国范围内无干扰素DAA治疗的扩大与HCV相关DC新发病例在人群层面的快速下降相关。
- 短期内大幅避免HCV相关DC是可行的,其他国家应努力实现同样目标。
研究设计与样本
- 基于苏格兰全国监测数据的记录链接研究,链接HCV诊断与临床数据库至医院和死亡登记。
主要发现
- DAA时代前后获得SVR的患者数总体扩大2.3倍,代偿期肝硬化患者中扩大5.9倍。
- DAA时代前,HCV相关DC年发病数从2000年30例增至2014年142例,增加4.6倍。
- DAA时代,DC新发病例下降51%至2018年69例,就诊时慢性感染者中下降67%。
- 趋势变化率比为0.88(95%CI 0.85-0.90)。
- 估计2015-18年期间避免330例DC病例。
临床怎么用
- 支持在人群中扩大DAA治疗以快速降低HCV相关DC负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Population-based studies demonstrating the clinical impact of interferon-free direct-acting antiviral (DAA) therapies are lacking. We examined the impact of the introduction of DAAs on HCV-related decompensated cirrhosis (DC) through analysis of population-based data from Scotland. DESIGN: Through analysis of national surveillance data (involving linkage of HCV diagnosis and clinical databases to hospital and deaths registers), we determined i) the scale-up in the number of patients treated and achieving a sustained viral response (SVR), and ii) the change in the trend of new presentations with HCV-related DC, with the introduction of DAAs. RESULTS: Approximately 11 000 patients had been treated in Scotland over the 8-year period 2010/11 to 2017/18. The scale-up in the number of patients achieving SVR between the pre-DAA and DAA eras was 2.3-fold overall and 5.9-fold among those with compensated cirrhosis (the group at immediate risk of developing DC). In the pre-DAA era, the annual number of HCV-related DC presentations increased 4.6-fold between 2000 (30) and 2014 (142). In the DAA era, presentations decreased by 51% to 69 in 2018 (and by 67% among those with chronic infection at presentation), representing a significant change in trend (rate ratio 0.88, 95% CI 0.85 to 0.90). With the introduction of DAAs, an estimated 330 DC cases had been averted during 2015-18. CONCLUSIONS: National scale-up in interferon-free DAA treatment is associated with the rapid downturn in presentations of HCV-related DC at the population-level. Major progress in averting HCV-related DC in the short-term is feasible, and thus other countries should strive to achieve the same.
引用
- Hutchinson SJ, Valerio H, McDonald SA, et al. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. Gut. 2020. PMID: 32217640. doi:10.1136/gutjnl-2019-320007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。